Dr. Mahsa Matloobi, MD

Dr. Matloobi practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Matloobi's NPI, 1609101211, was assigned on October 15, 2009. Dr. Matloobi graduated from Tehran University of Medical Sciences School of Medicine in 2005. Dr. Matloobi's New Mexico license number on file is MD2013-0224.

Dr. Matloobi's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Matloobi's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Matloobi is also affiliated with Long Beach Medical Center. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Matloobi to 2 more hospitals, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Matloobi practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Matloobi's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Matloobi is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Matloobi's licenses on file in 6 states: New Mexico, Alaska, Arizona, California, Maryland and Pennsylvania.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, epilepsy, fibromyalgia and chronic pain, head injury and hereditary polyneuropathy among the conditions Dr. Matloobi treats.

CMS data shows 736 Medicare services from Dr. Matloobi across 10 procedure codes in 2024, for 382 Medicare patients. Medicare paid $67,934 for them.

CMS counts 382 Medicare patients who saw Dr. Matloobi in 2024. The largest group is 75 to 84, with 149 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Matloobi's median patient age at 72, with 56% women.

In 2024, Dr. Matloobi wrote 480 Medicare Part D claims for 104 patients. 85% of them were for generic drugs. CMS names the drug for 362 of them, across 13 drugs with 11 or more claims each, at $32,748 in total drug cost. In 2023, CMS named 356 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Matloobi for performance year 2024, reported as part of a group. Dr. Matloobi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Matloobi as offering telehealth.

Dmand AI links 4 papers to Dr. Matloobi in 2009. 2009 was the busiest year, with 2. The most frequent topics are Blood, Methicillin-Resistant Staphylococcus aureus and Staphylococcal Infections. Dr. Matloobi's most frequent co-authors are Daniel M. Musher, MD, Mark Joseph Parta, MD and Thomas P. Giordano, MD.

CMS Open Payments shows 327 general payments to Dr. Matloobi from 50 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $1,304.

Dr. Matloobi graduated from Tehran University of Medical Sciences School of Medicine in 2005. Dr. Matloobi is a member of AAN.

Dr. Matloobi is in network with 8 carriers, including Aetna, Humana and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.